Bio Green Med Solution, Inc.BGMS

Bio Green Med Solution (BGMS) closed its latest quarter with $743K in revenue and a $197K net loss, per its 10-Q filing for the period ending March 31, 2026. The medical waste collection and recycling company, which recognizes revenue upon service delivery, reported just $3.3M in cash despite $7.6M in total assets. Its operating cash flow burned $278K, raising questions about sustainability even as it spends $848K annually on R&D (2025 10-K).

BGMS’s recent SEC filings paint a picture of strategic overreach. An 8-K filed June 22, 2026, disclosed shareholder votes at its Annual Meeting, though results were left cryptically 'indicated.' A June 16 S-4 filing revealed plans to leverage 'Strategic Capital Advisory' services, suggesting management is shopping for solutions to its cash crunch. The company’s inventory dropped $437K in Q1, which could signal efficient cost-cutting-or a fire sale of recycled materials.

Financials aside, BGMS’s core business remains narrow: medical waste services account for nearly all revenue. With liabilities at just $804K and equity of $6.8M, the balance sheet isn’t alarming, but free cash flow of -$278K and a diluted EPS of -$6.45 (2025 10-K) tell a grimmer story. The firm’s 5.5M diluted shares outstanding mean even modest losses per share add up quickly.

Chart watchers have little to cling to. No major exchanges or volume data are provided in the source rail, and the company’s $7.6M asset base barely covers its cash burn rate. The lack of buyback activity or dividend payments-combined with no mentioned guidance-leaves shareholders relying on strategic pivots rather than market mechanics.

What’s unproven? Whether BGMS can monetize its R&D or diversify beyond medical waste. The company’s future hinges on turning $3.3M in cash into growth before the burn rate turns catastrophic. Evidence of new contracts, inventory stabilization, or successful advisory outcomes would add credibility to its survival narrative.